HIGHLIGHTS
- who: Douglas D. Fang from the China for Therapeutic Innovation, University of Michigan, Huron Parkway have published the Article: Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models, in the Journal: (JOURNAL)
- what: Taken together the studies demonstrate that APG-2449 exerts potent and durable antitumor activity in human NSCLC and ovarian tumor models when administered alone or in combination with other A phase 1 clinical trial has been initiated to evaluate the safety and preliminary efficacy of APG-2449 in patients with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.